Doctors May Be Using Outdated Glaucoma Rule of Thumb

Why It Matters

The study undermines a century‑old treatment trigger, prompting ophthalmologists to adopt risk‑based, continuous IOP assessment, which could improve early intervention and patient outcomes.

Key Takeaways

• Study analyzed 184,504 eyes across seven academic centers.
• Treatment odds rise steadily from 17 to 21 mmHg.
• No clinical basis for 22 mmHg cutoff.
• Decision support tools could replace heuristic IOP thresholds.
• Continuous IOP risk challenges traditional glaucoma guidelines.

Pulse Analysis

Glaucoma remains a leading cause of irreversible blindness, and intra‑ocular pressure (IOP) has long served as the primary clinical lever for treatment decisions. Historically, ophthalmologists have relied on a simple heuristic: initiate therapy when IOP reaches or exceeds 22 mm Hg. This rule of thumb offered a clear, actionable threshold but ignored the nuanced relationship between pressure and optic nerve damage that modern imaging and longitudinal studies have begun to reveal.

The recent JAMA Ophthalmology analysis, leveraging the Sight Outcomes Research Collaborative database, examined 184,504 eyes from 94,232 patients across seven academic centers. By tracking over 1.8 million clinic visits, the researchers quantified treatment initiation rates at incremental IOP levels. Their data demonstrate a continuous rise in treatment odds beginning at 17 mm Hg, with a pronounced but not exclusive jump at 22 mm Hg. Crucially, the study finds no statistical justification for a binary cutoff, indicating that risk accumulates even at pressures previously considered safe. This evidence aligns with a growing body of literature that models glaucoma risk as a spectrum rather than a dichotomy.

For practitioners, the implications are twofold. First, reliance on a single pressure threshold may delay therapy for patients whose IOP sits just below 22 mm Hg yet carries significant risk. Second, the findings open the door for sophisticated clinical decision‑support systems that integrate continuous risk models, patient‑specific factors, and real‑time data. Such tools could reduce heuristic bias, standardize care, and ultimately improve visual outcomes. As insurers and health systems push for value‑based ophthalmic care, embracing a risk‑continuous approach may become both a clinical and economic imperative.